Tier 3 — preclinical
Lead Optimization: Synthesis and Biological Evaluation of Griseofulvin Derivatives as Novel SIRT6 Activators
ACS Medicinal Chemistry Letters
2026
17(3):662-669
Bibliography
- PubMed
- PMID 41847663
- PubMed Central
- PMC12989997
- Funding
- Funded by Virella d.o.o.; the work was conducted at the Faculty of Chemistry and Chemical Technology, University of Ljubljana.
- Competing interests
- The authors declared no competing financial interest.
Study snapshot
| Design | Medicinal-chemistry synthesis and biochemical SIRT6 activation study. |
|---|---|
| Model | Purified-enzyme and histone deacetylation assays. |
| Sample | Not applicable; biochemical experiments. |
| Intervention | Griseofulvin, forvisirvat and synthesized griseofulvin derivatives. |
| Duration | Not applicable. |
| Endpoints | SIRT6 activation fold change; dose-response behavior; H3K9 deacetylation; structure-activity relationships |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified



